Krishna Institute of Medical Sciences Limited KIMS NIFTY_SMALLNSEPHARMA
Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand in India. The company offers neurology, neurosurgery, psychiatry, and neuro rehabilitation; cardiology, cardiac and vascular surgery, heart transplant, and cardio rehabilitation; and pulmonology, interventional pulmonology, thoracic surgery, and lung transplant. It also provides medical and surgical gastroenterology, hepatobiliary pancreatic surgery, liver transplant, and bariatric surgery; ear, nose, throat, and head and neck surgery; and nephrology, urology, andrology, renal transplant, gynecology, urogynecology, IVF and art, fetal medicine, and obstetrics. In addition, the company offers orthopedics, arthroscopic and spine surgery, and ortho rehabilitation; medical surgical and radiation, and BMT and hematology; ophthalmology; dermatology, cosmetology, and plastic and reconstructive surgery; and clinical infectious diseases. Further, it provides imaging and interventional radiology; paediatrics and pediatric sub specialities, and neonatology; maxillo-facial surgery; OT and day care anaesthesia and pain medicine; and pathology, microbiology, and biochemistry. Additionally, the company offers molecular biology and clinical hematology; internal medicine, general surgery, and diabetology and endocrinology; and ICU, CTICU, SICU, NICU, PICU, neuro and ECMO ICU, and post transplant ICU services. Krishna Institute of Medical Sciences Limited was incorporated in 1973 and is based in Secunderabad, India.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 21.7% over 5 years.
CONS
- Trading at a high P/E of 126.7.
- Earnings shrank at -10.5% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KIMS Krishna Institute of Medical Sciences Limited NIFTY_SMALLNSEPHARMA | 758.85 | 126.69 | ₹30,364.54 Cr | - | 8.23% | 9.72% | 21.67% | -10.46% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Quarterly Results
Figures in INR.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 796.90 Cr | 871.60 Cr | 960.70 Cr | 997.70 Cr | 1,074.60 Cr |
| Cost of Revenue | 301.20 Cr | 335.00 Cr | 195.20 Cr | 196.90 Cr | 412.70 Cr |
| Gross Profit | 495.70 Cr | 536.60 Cr | 765.50 Cr | 800.80 Cr | 661.90 Cr |
| Operating Expenses | 350.30 Cr | 397.40 Cr | 627.60 Cr | 680.60 Cr | 540.40 Cr |
| Operating Income | 145.40 Cr | 139.20 Cr | 137.90 Cr | 120.20 Cr | 121.50 Cr |
| EBITDA | 213.30 Cr | 199.70 Cr | 207.90 Cr | 204.10 Cr | 207.90 Cr |
| Interest Expense | 26.70 Cr | 32.60 Cr | 45.00 Cr | 56.80 Cr | 68.10 Cr |
| Pretax Income | 134.00 Cr | 113.70 Cr | 96.80 Cr | 68.60 Cr | 54.80 Cr |
| Tax Provision | 27.90 Cr | 28.70 Cr | 24.80 Cr | 16.70 Cr | 21.70 Cr |
| Net Income | 101.80 Cr | 78.60 Cr | 66.90 Cr | 53.40 Cr | 42.50 Cr |
| Diluted EPS | 2.54 | 1.96 | 1.67 | 1.33 | 1.06 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 2,167.66 Cr | 2,474.00 Cr | 3,035.00 Cr | 3,904.60 Cr |
| Cost of Revenue | - | 827.08 Cr | 952.80 Cr | 1,126.40 Cr | 1,490.60 Cr |
| Gross Profit | - | 1,340.58 Cr | 1,521.20 Cr | 1,908.60 Cr | 2,414.00 Cr |
| Operating Expenses | - | 851.11 Cr | 1,018.70 Cr | 1,303.00 Cr | 1,895.20 Cr |
| Operating Income | - | 489.47 Cr | 502.50 Cr | 605.60 Cr | 518.80 Cr |
| EBITDA | - | 643.49 Cr | 652.40 Cr | 825.60 Cr | 819.60 Cr |
| Interest Expense | - | 29.32 Cr | 46.40 Cr | 90.30 Cr | 202.50 Cr |
| Pretax Income | - | 484.91 Cr | 459.50 Cr | 558.10 Cr | 333.90 Cr |
| Tax Provision | - | 119.09 Cr | 123.60 Cr | 143.30 Cr | 91.90 Cr |
| Net Income | - | 336.32 Cr | 310.00 Cr | 384.50 Cr | 241.40 Cr |
| Diluted EPS | 8.38 | 8.41 | 7.75 | 9.61 | - |
Compounded Sales Growth
| 5 Years: | 21.67% |
| 1 Year: | 34.80% |
Compounded Profit Growth
| 5 Years: | -10.46% |
| 1 Year: | -58.30% |
Stock Price Performance
| 1 Year: | +16.90% |
| 6 Months: | +11.85% |
| 3 Months: | +5.77% |
| 1 Month: | +14.07% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 2,941.30 Cr | 3,851.70 Cr | 5,736.00 Cr | 7,758.70 Cr |
| Current Assets | - | 477.64 Cr | 547.30 Cr | 697.30 Cr | 937.40 Cr |
| Cash & Equivalents | - | 61.61 Cr | 46.90 Cr | 56.00 Cr | 55.40 Cr |
| Inventory | - | 42.87 Cr | 49.40 Cr | 64.00 Cr | 96.90 Cr |
| Receivables | - | 252.65 Cr | 294.40 Cr | 395.40 Cr | 554.20 Cr |
| Total Liabilities | - | 1,003.34 Cr | 1,758.60 Cr | 3,317.20 Cr | 5,200.20 Cr |
| Current Liabilities | - | 296.47 Cr | 451.90 Cr | 836.20 Cr | 1,238.90 Cr |
| Long Term Debt | - | 497.44 Cr | 927.70 Cr | 1,654.10 Cr | 2,672.60 Cr |
| Total Debt | - | 678.17 Cr | 1,355.50 Cr | 2,556.70 Cr | 4,252.90 Cr |
| Total Equity | - | 1,669.54 Cr | 1,828.20 Cr | 2,137.80 Cr | 2,247.40 Cr |
| Shares Outstanding | - | 40.01 Cr | 40.01 Cr | 40.01 Cr | 40.01 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 432.09 Cr | 521.20 Cr | 581.80 Cr | 510.80 Cr |
| Investing Cash Flow | - | -546.89 Cr | -752.60 Cr | -1,116.20 Cr | -1,451.70 Cr |
| Financing Cash Flow | - | 19.64 Cr | 216.70 Cr | 543.10 Cr | 940.30 Cr |
| Capital Expenditure | - | -574.52 Cr | -647.30 Cr | -1,008.90 Cr | -1,427.90 Cr |
| Free Cash Flow | - | -142.44 Cr | -126.10 Cr | -427.10 Cr | -917.10 Cr |
| Net Change in Cash | - | -95.17 Cr | -14.70 Cr | 8.70 Cr | -60.00 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 61.8% | 61.5% | 62.9% | 61.8% |
| Operating Margin % | - | 22.6% | 20.3% | 20.0% | 13.3% |
| Net Margin % | - | 15.5% | 12.5% | 12.7% | 6.2% |
| ROE % | - | 20.1% | 17.0% | 18.0% | 10.7% |
| ROCE % | - | 18.5% | 14.8% | 12.4% | 8.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KIMS